中國抗體-B(03681.HK):採納股份獎勵計劃
格隆匯 2 月 4日丨中國抗體-B(03681.HK)宣佈,於2021年2月4日,公司已採納該計劃以通過向董事、高級管理層、僱員及顧問提供擁有公司股權的機會,激勵彼等對集團作出貢獻,並吸引、激勵及挽留熟練且有經驗的人員致力於集團未來發展及擴張,以促進公司業務成功。
在未經董事會批准的情況下,倘授出獎勵會導致根據該計劃的全部授出所涉及股份總數超過採納日期已發行股份數目的5%,則公司不得再授出獎勵。
根據該計劃向一名選定參與者授出的獎勵股份總數不得超過於採納日期已發行股份總數的2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.